Ther Apher Dial. 2021 Aug 11. doi: 10.1111/1744-9987.13722. Online ahead of print.
ABSTRACT
Long term dialysis involves a chronic inflammatory state and produces a high prevalence of vitamin D deficiency. A clinical trial was conducted in hemodialysis with serum 25-hydroxyvitamin D (25[OH]D) level < 30 ng/mL. The conventional-group (N = 35) and the high-dose group (N = 35) were treated with ergocalciferol according to the K/DOQI guidelines and double dosage of ergocalciferol from the recommendation for 8 weeks, respectively. The main outcomes were measured by serum 25[OH]D and interleukin-6 (IL-6). At the end of 8 weeks, a statistically significantly greater increase was observed of mean serum 25[OH]D levels and decrease of mean PTH levels in the high-dose group compared with the conventional-dose group. The high dose group had higher achievement of vitamin D sufficiency than the conventional-dose group (97.4% vs. 76.4%, P = 0.012). No significance difference was found in mean changes of serum IL-6 level in the both groups, except subgroup patients with vitamin D deficiency or serum 25[OH]D < 20 ng/mL, high dose treatment suppressed serum IL-6 level (-2.67 pg/mL [IQR -6.56 to -0.17], P = 0.039). No differences were observed between the two groups in adverse events. Oral high-dose ergocalciferol supplementation has achieved higher vitamin D sufficiency than standard dose in ESRD patients on dialysis.
PMID:34378863 | DOI:10.1111/1744-9987.13722
